These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Overview of pathophysiology and rationale for treatment of sickle cell anemia. Rodgers GP Semin Hematol; 1997 Jul; 34(3 Suppl 3):2-7. PubMed ID: 9317195 [TBL] [Abstract][Full Text] [Related]
5. Established and experimental treatments for sickle cell disease. De Franceschi L; Corrocher R Haematologica; 2004 Mar; 89(3):348-56. PubMed ID: 15020275 [TBL] [Abstract][Full Text] [Related]
6. The mechanism of action of two anti-sickling agents: sodium cyanate and glyceraldehyde. Manning JM; Acharya AS Am J Pediatr Hematol Oncol; 1984; 6(1):51-4. PubMed ID: 6711764 [TBL] [Abstract][Full Text] [Related]
7. Viscosity and filtrability measurements of sickle-cell suspensions in the development of anti-sickling drugs. Ohnishi ST Blood Cells; 1982; 8(1):79-87. PubMed ID: 7115980 [TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea in the treatment of sickle-cell anemia. Howard LW; Kennedy LD Ann Pharmacother; 1997 Nov; 31(11):1393-6. PubMed ID: 9391697 [TBL] [Abstract][Full Text] [Related]
9. A new approach to the treatment of sickle cell anemia. Milosz A; Settle W Res Commun Chem Pathol Pharmacol; 1975 Sep; 12(1):137-46. PubMed ID: 1188180 [TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea for children with sickle cell disease. Heeney MM; Ware RE Pediatr Clin North Am; 2008 Apr; 55(2):483-501, x. PubMed ID: 18381097 [TBL] [Abstract][Full Text] [Related]
11. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo? Oder E; Safo MK; Abdulmalik O; Kato GJ Br J Haematol; 2016 Oct; 175(1):24-30. PubMed ID: 27605087 [TBL] [Abstract][Full Text] [Related]
12. Quantitative prediction of erythrocyte sickling for the development of advanced sickle cell therapies. Lu L; Li Z; Li H; Li X; Vekilov PG; Karniadakis GE Sci Adv; 2019 Aug; 5(8):eaax3905. PubMed ID: 31457104 [TBL] [Abstract][Full Text] [Related]
13. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin. Henry ER; Metaferia B; Li Q; Harper J; Best RB; Glass KE; Cellmer T; Dunkelberger EB; Conrey A; Thein SL; Bunn HF; Eaton WA Blood; 2021 Sep; 138(13):1172-1181. PubMed ID: 34197597 [TBL] [Abstract][Full Text] [Related]
14. Effects of carbon dioxide and pH variations in vitro on blood respiratory functions, red blood cell volume, transmembrane pH gradients, and sickling in sickle cell anemia. Ueda Y; Bookchin RM J Lab Clin Med; 1984 Aug; 104(2):146-59. PubMed ID: 6431043 [TBL] [Abstract][Full Text] [Related]
15. The effect of the antisickling compound GBT1118 on the permeability of red blood cells from patients with sickle cell anemia. Al Balushi H; Dufu K; Rees DC; Brewin JN; Hannemann A; Oksenberg D; Lu DC; Gibson JS Physiol Rep; 2019 Mar; 7(6):e14027. PubMed ID: 30916477 [TBL] [Abstract][Full Text] [Related]
16. New advances in the treatment of sickle cell disease: focus on perioperative significance. Dix HM AANA J; 2001 Aug; 69(4):281-6. PubMed ID: 11759366 [TBL] [Abstract][Full Text] [Related]
17. New antisickling agents. Labie D Haematologia (Budap); 1983; 16(1-4):105-8. PubMed ID: 6679483 [TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea therapy: improving the lives of patients with sickle cell disease. Anderson N Pediatr Nurs; 2006; 32(6):541-3. PubMed ID: 17256291 [TBL] [Abstract][Full Text] [Related]
19. Effects of cetiedil on monovalent cation permeability in the erythrocyte: an explanation for the efficacy of cetiedil in the treatment of sickle cell anemia. Berkowitz LR; Orringer EP Blood Cells; 1982; 8(2):283-8. PubMed ID: 7159752 [TBL] [Abstract][Full Text] [Related]